Literature DB >> 17438170

Enhancing compliance with Medicare guidelines for surgical infection prevention: experience with a cross-disciplinary quality improvement team.

Laurence E McCahill1, John W Ahern, Linda A Gruppi, James Limanek, Gail A Dion, Jessica A Sussman, Christina B McCaffrey, Diane B Leary, Margaret B Lesage, Richard M Single.   

Abstract

HYPOTHESIS: The Center for Medicare and Medicaid Services instituted standardized reporting of measures aimed at surgical infection prevention (SIP). The complexity and number of medical personnel involved in antibiotic administration requires multiple disciplines to successfully improve compliance.
DESIGN: Survey study.
SETTING: Tertiary care university hospital. PATIENTS: All patients undergoing the following operations from July 2004 through December 2005 were monitored for compliance with SIP: (1) coronary artery bypass graft, (2) other cardiac, (3) vascular, (4) hysterectomy, (5) colon resection, (6) hip arthroplasty, and (7) knee arthroplasty. INTERVENTION: A team including a surgeon, an anesthesiologist, nurses (preoperative, operating room, and floor), a pharmacist, a hospital infection control committee member, and quality improvement and operations specialists was created in July 2004. Hospital guidelines for SIP were defined, personnel roles defined and processes standardized, and communication/education for health care professionals was enhanced. MAIN OUTCOME MEASURES: Compliance with 3 SIP measures over 3 consecutive periods of 6 months each: (1) percentage of patients receiving antibiotics within 1 hour of incision, (2) percentage of patients with appropriately selected antibiotics, and (3) percentage of patients with antibiotics discontinued within 24 hours of operation end time.
RESULTS: One thousand seventy-two patients were monitored. Measure 1 compliance improved from 72.25% to 83.78% (P<.001, Cochran-Armitage trend test); improvement or high performance (>90% compliance) was demonstrated in 5 of 7 services. Measure 2 compliance remained uniformly high (approximately 98%). Measure 3 compliance improved from 54.5% to 87.16% (P<.001); improvement was seen in 5 of 7 services.
CONCLUSIONS: The clearly defined roles of a cross-disciplinary team and the process improvements discussed in this article can easily be implemented in other institutions. These elements were integral to our success in improving the timely delivery and discontinuation of prophylactic surgical antibiotics.

Entities:  

Mesh:

Year:  2007        PMID: 17438170     DOI: 10.1001/archsurg.142.4.355

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  5 in total

Review 1.  Surgical site infection: poor compliance with guidelines and care bundles.

Authors:  David J Leaper; Judith Tanner; Martin Kiernan; Ojan Assadian; Charles E Edmiston
Journal:  Int Wound J       Date:  2014-02-25       Impact factor: 3.315

Review 2.  Mechanical bowel preparation in intestinal surgery: a meta-analysis and review of the literature.

Authors:  Carlos E Pineda; Andrew A Shelton; Tina Hernandez-Boussard; John M Morton; Mark L Welton
Journal:  J Gastrointest Surg       Date:  2008-07-12       Impact factor: 3.452

3.  Implementing a standardized perioperative antibiotic prophylaxis protocol for neonates undergoing cardiac surgery.

Authors:  Meghan T Murray; Rozelle Corda; Rebecca Turcotte; Emile Bacha; Lisa Saiman; Ganga Krishnamurthy
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

4.  Timing of surgical antibiotic prophylaxis administration: complexities of analysis.

Authors:  Carrie Cartmill; Lorelei Lingard; Glenn Regehr; Sherry Espin; John Bohnen; Ross Baker; Lorne Rotstein
Journal:  BMC Med Res Methodol       Date:  2009-06-23       Impact factor: 4.615

Review 5.  Implementation methods of infection prevention measures in orthopedics and traumatology - a systematic review.

Authors:  Benedikt Marche; Meike Neuwirth; Christiane Kugler; Bertil Bouillon; Frauke Mattner; Robin Otchwemah
Journal:  Eur J Trauma Emerg Surg       Date:  2020-09-10       Impact factor: 3.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.